Nido Biosciences
Biotechnology company leveraging the small intestinal microbiome to develop novel therapeutics for gastrointestinal and metabolic diseases.
Website
https://www.nidobio.comLocation
Boston, Massachusetts, USA
Founded
2019
Investors
1
Categories
biotech, microbiome, therapeutics, gastrointestinal, cardiovascular
Notes
Nido Biosciences is a biotechnology company focused on developing therapeutics based on the small intestinal microbiome. While most microbiome research has focused on the large intestine (colon), Nido is pioneering work on the underexplored small intestine microbiome and its role in disease.
The company develops therapies for gastrointestinal and metabolic diseases using insights from its proprietary small intestine microbiome research platform.
Team
- Rabia Gurses Saddington - Chief Executive Officer
- Diego Rey, Ph.D. - Co-Founder & CSO
Additional Research Findings
- Founded in 2019 in Boston, Massachusetts
- Portfolio company of Abingworth
- Focus on small intestinal microbiome - a relatively unexplored area
- Developing therapeutics for GI and metabolic conditions
- Proprietary research platform for small intestine microbiome
- Part of the growing microbiome therapeutics space
- Spin-out from academic microbiome research
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Abingworth | London, UK / Boston, USA | biotech-focused | seedseries-a+3 | 34 |